<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 6.2: Phase I: Functionalization and the Cytochrome P450 System</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - GREEN theme for Detox */
        .module-header {
            background: linear-gradient(135deg, #065f46 0%, #059669 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #059669;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #059669;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #059669;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0fdf4;
            border: 2px solid #10B981;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #059669;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #059669;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #10B981;
        }

        .term-item .term {
            font-weight: 700;
            color: #059669;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #059669;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome Box */
        .welcome-box {
            background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #bbf7d0;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #059669;
        }

        /* Stats Box */
        .stats-box {
            background: linear-gradient(135deg, #059669 0%, #10B981 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Table Styles */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            background: white;
        }

        .data-table th {
            background: #f8f9fa;
            color: #059669;
            font-weight: 700;
            text-align: left;
            padding: 15px;
            border-bottom: 2px solid #e5e5e5;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #eee;
        }

        /* Case Study */
        .case-study {
            background: #f8f9fb;
            border-radius: 16px;
            margin: 40px 0;
            overflow: hidden;
            border: 1px solid #e5e5e5;
        }

        .case-study-header {
            background: #059669;
            padding: 20px 30px;
            color: white;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #eee;
        }

        .patient-avatar {
            width: 50px;
            height: 50px;
            background: #10B981;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            color: white;
            font-size: 22px;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            padding: 22px;
            margin-bottom: 16px;
            border-radius: 12px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #059669;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0f8f0;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f5f5f5;
            padding: 25px;
            margin-top: 35px;
            border-radius: 8px;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #fff;
            border-top: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            color: #059669;
            margin-bottom: 15px;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 6: The P.U.R.I.F.Y. Protocolâ„¢</p>
            <h1 class="lesson-title">Lesson 6.2: Phase I: Functionalization and the Cytochrome P450 System</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 2 of 6</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Role of Functionalization</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The CYP450 Enzyme Superfamily</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Mechanisms of Action</a></li>
                <li><a href="#section4"><span class="section-num">4</span>The Reactive Intermediate Risk</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Nutrient Co-factors for Phase I</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Clinical Induction & Inhibition</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the biochemical purpose of "Functionalization" in the biotransformation process.</li>
                <li>Identify the primary Cytochrome P450 (CYP) enzymes responsible for metabolizing common toxins and medications.</li>
                <li>Explain the metabolic consequences of Phase I and Phase II "uncoupling" and the generation of reactive oxygen species (ROS).</li>
                <li>List the essential micronutrient co-factors required to maintain optimal Phase I enzymatic activity.</li>
                <li>Differentiate between enzymatic inducers and inhibitors and their impact on client toxicity profiles.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>The Engine of Restoration</h3>
            <p>In the "Restore Bio-Transformation" phase of the P.U.R.I.F.Y. Protocolâ„¢, we shift our focus to the internal machinery of the liver. While previous modules focused on clearing the exit routes, we now address the chemical processing plant itself. <span class="highlight">Phase I is the critical first step</span> that prepares lipophilic (fat-soluble) toxins for final neutralisation. Without a robust Phase I system, toxins remain sequestered in adipose and neural tissue; however, without proper management, Phase I can inadvertently increase the toxicity of the body's internal environment.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">Functionalization</p>
                    <p class="definition">The process of adding or exposing a reactive "handle" (such as a hydroxyl group) on a toxic molecule to make it more chemically active.</p>
                </div>
                <div class="term-item">
                    <p class="term">CYP450</p>
                    <p class="definition">A superfamily of heme-containing enzymes located primarily in the endoplasmic reticulum of hepatocytes, responsible for the oxidation of organic substances.</p>
                </div>
                <div class="term-item">
                    <p class="term">Reactive Intermediate</p>
                    <p class="definition">A highly unstable, often more toxic metabolite produced during Phase I that must be immediately processed by Phase II enzymes.</p>
                </div>
                <div class="term-item">
                    <p class="term">Enzymatic Induction</p>
                    <p class="definition">An increase in the synthesis and activity of enzymes, often caused by chronic exposure to a specific substance (e.g., alcohol or caffeine).</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Role of Functionalization</h2>
        <p>Most environmental toxins, pharmaceutical drugs, and endogenous hormones (like estrogen) are <span class="highlight">lipophilic</span>, meaning they dissolve in fat but not in water. This characteristic allows them to easily pass through cell membranes, but it makes them nearly impossible for the kidneys or bile to excrete. The primary goal of biotransformation is to convert these fat-loving substances into water-soluble (hydrophilic) metabolites.</p>

        <p>Phase I, or <strong>Functionalization</strong>, serves as the preparatory stage. It doesn't necessarily make the toxin less harmful; rather, it introduces a "functional group"â€”typically a hydroxyl (-OH), carboxyl (-COOH), or amino (-NH2) group. Think of this as adding a "hook" to a smooth surface so that Phase II enzymes can later grab onto it and attach a bulky, water-soluble molecule like glutathione or sulfate.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">57</div>
                    <div class="stat-label">Active CYP Genes in Humans</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">75%</div>
                    <div class="stat-label">Drugs Metabolized by Phase I</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">10x</div>
                    <div class="stat-label">Toxicity of Intermediates</div>
                </div>
            </div>
        </div>

        <h2 id="section2">The CYP450 Enzyme Superfamily</h2>
        <p>The heavy lifting of Phase I is performed by the <span class="highlight">Cytochrome P450 (CYP450)</span> system. These enzymes are named for their pigment (P) and their light absorption at 450 nm when bound to carbon monoxide. While found in the lungs, kidneys, and gut, their highest concentration is in the liver.</p>

        <p>Not all CYP enzymes are created equal. They are categorized into families (CYP1, CYP2, CYP3), subfamilies (A, B, C), and specific gene products. For the Detox Specialist, understanding the primary "workhorse" enzymes is vital for assessing client symptoms and potential genetic roadblocks.</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Enzyme</th>
                        <th>Primary Targets</th>
                        <th>Common Inducers</th>
                        <th>Common Inhibitors</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>CYP1A2</strong></td>
                        <td>Caffeine, Theophylline, Estrogen</td>
                        <td>Charbroiled foods, Cruciferous veg, Smoking</td>
                        <td>Turmeric, Cumin, Quercetin</td>
                    </tr>
                    <tr>
                        <td><strong>CYP2E1</strong></td>
                        <td>Alcohol, Acetaminophen, Benzene</td>
                        <td>Ethanol, High-fat diets, Ketones</td>
                        <td>Watercress, Garlic (diallyl sulfide)</td>
                    </tr>
                    <tr>
                        <td><strong>CYP3A4</strong></td>
                        <td>50% of all drugs, Steroid hormones</td>
                        <td>St. John's Wort, Glucocorticoids</td>
                        <td>Grapefruit juice, Bergapten</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">Mechanisms of Action</h2>
        <p>Phase I reactions are primarily oxidative. The CYP450 enzyme uses oxygen and a reducing agent (NADPH) to "attack" the toxin. The general reaction can be summarized as follows:</p>
        <p style="text-align: center; font-family: monospace; background: #f0f0f0; padding: 15px; border-radius: 8px;">
            RH + O<sub>2</sub> + NADPH + H<sup>+</sup> â†’ ROH + H<sub>2</sub>O + NADP<sup>+</sup>
        </p>
        <p>In this equation, <strong>RH</strong> is the toxin and <strong>ROH</strong> is the now-functionalized metabolite. While oxidation is the most common reaction, Phase I also utilizes:</p>
        <ul>
            <li><strong>Reduction:</strong> The gain of electrons (often occurring in low-oxygen environments).</li>
            <li><strong>Hydrolysis:</strong> The addition of water to break a chemical bond.</li>
            <li><strong>Dealkylation:</strong> The removal of alkyl groups.</li>
        </ul>

        <div class="case-study">
            <div class="case-study-header">
                <p class="box-label">Case Study: The "Jittery" Executive</p>
                <p class="subtitle">Clinical Application of CYP1A2 Assessment</p>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">M</div>
                    <div class="patient-info">
                        <h4>Mark S., 42</h4>
                        <p>Symptoms: Anxiety, insomnia, and palpitations after one cup of coffee.</p>
                    </div>
                </div>
                <p><strong>Presentation:</strong> Mark reported that even a small amount of caffeine at 8:00 AM would prevent him from sleeping at 11:00 PM. He also noted sensitivity to "smells" like perfume and exhaust.</p>
                <p><strong>Intervention:</strong> Based on the P.U.R.I.F.Y. Protocolâ„¢, we identified a likely "slow metabolizer" status for <strong>CYP1A2</strong>. We implemented support for Phase I co-factors and removed inhibitors like excessive turmeric supplementation he was taking for "inflammation."</p>
                <p><strong>Outcome:</strong> By supporting the CYP1A2 pathway with moderate cruciferous vegetable intake (inducer) and ensuring adequate B-vitamin status, Mark's caffeine clearance improved by 40% (measured via subjective tolerance), and his systemic "chemical sensitivity" decreased.</p>
            </div>
        </div>

        <h2 id="section4">The "Reactive Intermediate" Paradox</h2>
        <p>A critical concept for any practitioner is the danger of <span class="highlight">Pathological Detoxification</span>. This occurs when Phase I activity is highly induced (running fast) but Phase II activity is sluggish or nutrient-depleted. Because Phase I often creates "reactive intermediates"â€”which are essentially free radicalsâ€”they can cause significant cellular damage if not immediately neutralized.</p>

        <p>For example, the metabolism of acetaminophen (Tylenol) via CYP2E1 produces <strong>NAPQI</strong>, a highly toxic intermediate. Under normal conditions, Phase II (Glutathione conjugation) neutralizes it instantly. If glutathione is depleted, NAPQI binds to liver cell proteins, causing necrosis. This is why the P.U.R.I.F.Y. Protocolâ„¢ emphasizes <strong>simultaneous</strong> support for both phases.</p>

        <h2 id="section5">Nutrient Co-factors: Fueling the CYP450 Engine</h2>
        <p>Phase I is an energy-intensive process that requires a specific "kit" of micronutrients to function. Without these co-factors, the CYP enzymes cannot bind oxygen or process the toxin, leading to a "backup" of toxins in the tissues.</p>

        <div class="key-terms-box">
            <p class="box-label">Essential Phase I Co-factors</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">B-Vitamins (B2, B3, B6, B12, Folate)</p>
                    <p class="definition">Necessary for the production of NADPH and the methylation cycles that support enzyme synthesis.</p>
                </div>
                <div class="term-item">
                    <p class="term">Glutathione</p>
                    <p class="definition">While primarily a Phase II agent, it acts as a crucial antioxidant to quench ROS generated during Phase I.</p>
                </div>
                <div class="term-item">
                    <p class="term">Flavonoids</p>
                    <p class="definition">Compounds like ellagic acid (pomegranate) and milk silybin protect the liver during the oxidation process.</p>
                </div>
                <div class="term-item">
                    <p class="term">Trace Minerals</p>
                    <p class="definition">Iron (for the heme center), Copper, Magnesium, and Zinc are required for enzymatic structural integrity.</p>
                </div>
            </div>
        </div>

        <h2 id="section6">Clinical Induction & Inhibition</h2>
        <p>Practitioners must be aware of how a client's lifestyle "tunes" their Phase I system. <span class="highlight">Inducers</span> make the system work harder, while <span class="highlight">Inhibitors</span> slow it down. Neither is inherently "good" or "bad"â€”the goal is balance.</p>

        <ul>
            <li><strong>Inducers:</strong> Chronic alcohol consumption, cigarette smoke, charbroiled meats (PAHs), and cruciferous vegetables (Indole-3-Carbinol).</li>
            <li><strong>Inhibitors:</strong> Grapefruit juice (naringenin), curcumin (high doses), certain medications (ketoconazole), and heavy metals (lead, mercury).</li>
        </ul>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">1. Why is Phase I often described as making a toxin "more dangerous" before it makes it "safe"?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Phase I functionalization introduces reactive "handles" (like hydroxyl groups) to the molecule. This creates highly reactive intermediates (free radicals) that are often more chemically aggressive and toxic than the original fat-soluble toxin. They must be immediately processed by Phase II to prevent cellular damage.</div>
            </div>

            <div class="question-item">
                <p class="question-text">2. A client drinks a liter of grapefruit juice daily while taking several medications. What is the likely metabolic consequence?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Grapefruit juice contains furanocoumarins that inhibit the CYP3A4 enzyme. This slows down the Phase I metabolism of medications, leading to higher-than-intended levels of the drugs in the bloodstream, increasing the risk of toxicity and side effects.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Phase I (Functionalization) prepares lipophilic toxins for Phase II by adding reactive chemical "handles."</li>
                <li>The Cytochrome P450 (CYP450) system is the primary enzymatic engine for Phase I.</li>
                <li>Uncoupled Phase I (high Phase I, low Phase II) leads to oxidative stress and cellular damage due to reactive intermediates.</li>
                <li>B-vitamins, glutathione, and trace minerals are mandatory co-factors for healthy Phase I function.</li>
                <li>Clinical success requires balancing enzymatic induction and inhibition based on the client's unique exposures and genetics.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Zanger, U. M., & Schwab, M. (2013). "Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation." <i>Pharmacology & Therapeutics</i>.</li>
                <li>Liska, D. J. (1998). "The detoxification system." <i>Alternative Medicine Review</i>.</li>
                <li>Guengerich, F. P. (2008). "Cytochrome p450 and chemical toxicology." <i>Chemical Research in Toxicology</i>.</li>
                <li>Hodges, R. E., & Minich, D. M. (2015). "Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical Application." <i>Journal of Nutrition and Metabolism</i>.</li>
                <li>Whirl-Carrillo, M., et al. (2012). "Pharmacogenomics knowledge for personalized medicine." <i>Clinical Pharmacology & Therapeutics</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Detox & Cleanse Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>